Background Knowledge: Topics

Evidence-based dossiers on common questions about autism and ADHD. Every statement is backed by concrete, checkable studies; all sources have been verified against PubMed. Neutral knowledge-sharing – not diagnosis, not counseling, no promises of a cure.

Genetic clustering and heritability of autism and ADHD in families

Autism and ADHD are among the most strongly genetically influenced neurodivergent traits in childhood and adolescence. Large twin and cohort studies estimate the heritability of autism at roughly 50% to over 80%, depending on the modeling assumptions, and around 74% for ADHD. Autism clusters clearly within families: recurrence risk is markedly elevated in siblings, and especially in identical twins. At the same time, genome-wide studies show that many common genetic variants, each with a small effect, contribute to susceptibility, and that there is genetic overlap with other traits.

Key findings

A meta-analysis of twin studies estimated the heritability of autism at 64-91% (twin correlation of 0.98 in identical twins, 0.53-0.67 in fraternal twins), pointing to strong genetic effects (Tick 2016).
In a population-based cohort from five countries, the cross-country median heritability of autism was 80.8% (95% CI 73.2-85.5%), while maternal effects explained only 0.4-1.6% (Bai 2019).
A large Swedish cohort study estimated the heritability of autism at 0.50 (95% CI 0.45-0.56) (Sandin 2014).
In a reanalysis of the same Swedish cohort, the best-fitting model yielded a heritability of 83% (non-shared environment 17%) – markedly higher than the roughly 50% from the original analysis, showing how strongly the estimate depends on the modeling assumptions (Sandin 2017).
The relative recurrence risk for autism in the same cohort was 10.3 for full siblings and 153.0 for identical twins, illustrating the familial clustering (Sandin 2014).
ADHD shows a high heritability of 74%, of which roughly a third is attributable to a polygenic component made up of many common variants with small effects (Faraone & Larsson 2019).
A twin study using the Swedish Twin Register (59,514 twins) estimated the heritability of clinically diagnosed ADHD at 0.88 (95% CI 0.83-0.92) across the lifespan and at 0.72 (0.56-0.84) in adulthood; shared environmental influences were negligible (Larsson 2014).
Autism and ADHD co-aggregate within families: in a register study of 1,899,654 people, relatives of autistic individuals had an elevated risk of ADHD, strongest in identical twins (odds ratio 17.8), followed by fraternal twins (4.3) and full siblings (4.6) – a pattern pointing to a shared genetic basis for both conditions (Ghirardi 2018).
The largest genome-wide association study of autism to date identified five genome-wide significant loci and showed considerable genetic overlap with other traits such as schizophrenia, depression, and educational attainment (Grove 2019).

Context & limitations

The findings come mainly from twin and large population-based cohort studies, as well as genome-wide association studies. Heritability is a statistical measure at the population level: it describes what proportion of the differences between people in a population is associated with genetic differences, and it says nothing about any individual person or a fixed cause in a specific case. The fact that heritability estimates range from roughly 50% to over 80% (Tick 2016; Bai 2019; Sandin 2014; Sandin 2017) shows how strongly such figures depend on the study population, diagnostic criteria, and modeling assumptions. Twin and cohort designs demonstrate genetic contributions and familial clustering but do not identify any specific responsible genes; genome-wide studies such as Grove (2019) show a polygenic pattern made up of many variants, each with a small effect, and genetic overlap between traits. A high genetic contribution does not mean environmental factors play no role; the studies cited always estimate genetic and non-genetic proportions jointly. For ADHD there is both an authoritative review (Faraone & Larsson 2019: heritability 74%) and a twin study of clinically diagnosed ADHD (Larsson 2014: 0.88), as well as a large register study on familial co-aggregation with autism (Ghirardi 2018); differences in the heritability figures reflect methodology and sample (e.g., self-report vs. clinical diagnosis). These figures are scientific estimates, not a basis for individual diagnoses or prognoses.

Studies & sources

Tick B et al. (2016). Heritability of autism spectrum disorders: a meta-analysis of twin studies. J Child Psychol Psychiatry 57(5):585-95. DOI · PMID 26709141
Twin meta-analysis (systematic review) · 7 twin studies in the meta-analysis (of 13 identified); plus a population sample of 6,413 twin pairs
Bai D et al. (2019). Association of Genetic and Environmental Factors With Autism in a 5-Country Cohort. JAMA Psychiatry 76(10):1035-1043. DOI · PMID 31314057
Population-based multinational cohort study (5 countries) · 2,001,631 people from Denmark, Finland, Sweden, Israel and Western Australia, of whom 22,156 had an ASD diagnosis
Sandin S et al. (2017). The Heritability of Autism Spectrum Disorder. JAMA 318(12):1182-1184. DOI · PMID 28973605
Reanalysis of a Swedish cohort (research letter) · Swedish birth cohort (reanalysis of the Sandin 2014 data with alternative modeling assumptions)
Sandin S et al. (2014). The familial risk of autism. JAMA 311(17):1770-7. DOI · PMID 24794370
Population-based cohort study (familial recurrence risk / heritability) · 2,049,973 children born in Sweden 1982-2006 (incl. 37,570 twin pairs, 2,642,064 full-sibling pairs), 14,516 with ASD
Faraone SV, Larsson H (2019). Genetics of attention deficit hyperactivity disorder. Mol Psychiatry 24(4):562-575. DOI · PMID 29892054
Review (family, twin, adoption and GWAS studies) · Narrative synthesis of family, twin, adoption and genome-wide association studies (GWAS) on ADHD
Larsson H, Chang Z, D'Onofrio BM, Lichtenstein P. (2014). The heritability of clinically diagnosed attention deficit hyperactivity disorder across the lifespan. Psychol Med 44(10):2223-9. DOI · PMID 24107258
Twin study (Swedish Twin Register) · 59,514 twins
Ghirardi L, Brikell I, Kuja-Halkola R, et al. (2018). The familial co-aggregation of ASD and ADHD: a register-based cohort study. Mol Psychiatry 23(2):257-262. DOI · PMID 28242872
Register-based cohort study (familial co-aggregation) · 1,899,654 people (Sweden)
Grove J et al. (2019). Identification of common genetic risk variants for autism spectrum disorder. Nat Genet 51(3):431-444. DOI · PMID 30804558
Genome-wide association meta-analysis (GWAS) · 18,381 people with ASD and 27,969 controls

Related individual studies in the knowledge base (PubMed): 37031194 · 37781978 · 36450307

Is there "the autism gene"? Why autism is polygenic

Research has not found a single "autism gene," but rather a polygenic architecture: a very large number of genetic variants, each with a small effect, act together, complemented by rarer variants with a larger individual effect. Large genome-wide studies estimate heritability at roughly half and attribute the majority of it to common variants. At the same time, exome and CNV studies identify dozens to hundreds of individual risk genes and regions, illustrating the enormous genetic diversity behind the spectrum.

Key findings

The narrow-sense heritability of autism is around 52.4 percent and is carried predominantly by common genetic variants (Gaugler 2014).
Rare de novo mutations do contribute to genetic expression in individual cases, but explain only around 2.6 percent of the variance in liability (Gaugler 2014).
The largest ASD GWAS meta-analysis to date (18,381 cases, 27,969 controls) found five genome-wide significant loci and confirmed a strongly polygenic architecture with many variants of small individual effect (Grove 2019).
A large exome study (35,584 samples, of which 11,986 had ASD) identified 102 risk genes, 13 of which lie in regions of recurrent copy-number variation (Satterstrom 2020).
An analysis of 2,591 families found 71 risk loci, consisting of 6 CNV regions (including 16p11.2, 22q11.2, 7q11.23) and 65 risk genes (Sanders 2015).
Coding de novo mutations contribute to around 30 percent of all simplex diagnoses and 45 percent of diagnoses in girls (Iossifov 2014).
Estimates suggest that gene-disrupting mutations in around 400 different genes can contribute to the autism spectrum – evidence of extreme genetic heterogeneity (Iossifov 2014).

Context & limitations

The findings come from different study designs that answer different questions: population-based heritability studies (Gaugler 2014) estimate how much of the trait variation in a population is genetically explainable; genome-wide association studies (Grove 2019) search for common variants with small effects; exome and CNV studies (Satterstrom 2020, Sanders 2015, Iossifov 2014) identify individual, often rare, risk genes and regions. The percentages refer to different quantities and must not be compared directly with one another: the figure of 2.6 percent (Gaugler 2014) denotes the share of the variance in liability, while the 30 percent (Iossifov 2014) refers to the share of affected simplex cases with a relevant de novo mutation. Overall, the data consistently show that autism is polygenic and that there is no single responsible gene; individual loci such as 16p11.2 each explain only a small proportion of cases. Heritability is a population-level measure and makes no statement about individual children; the studies describe genetic associations, not cause-and-effect chains for the individual case. Grove 2019 also points to loci shared with other traits, which further complicates delineating individual "autism genes."

Studies & sources

Grove J et al. (2019). Identification of common genetic risk variants for autism spectrum disorder. Nat Genet 51(3):431-444. DOI · PMID 30804558
Genome-wide association meta-analysis (GWAS) · 18,381 ASD cases and 27,969 controls
Gaugler T et al. (2014). Most genetic risk for autism resides with common variation. Nat Genet 46(8):881-5. DOI · PMID 25038753
Population-based epidemiological heritability study (Sweden) · Swedish epidemiological cohort (population-based)
Satterstrom FK et al. (2020). Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell 180(3):568-584.e23. DOI · PMID 31981491
Exome sequencing study (case-control and de novo analysis) · 35,584 samples in total, of which 11,986 had ASD
Sanders SJ et al. (2015). Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. Neuron 87(6):1215-1233. DOI · PMID 26402605
Genomic association study (de novo CNV and exome analysis, TADA) · 2,591 families (Simons Simplex Collection) plus additional AGP/ASC data
Iossifov I et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. Nature 515(7526):216-21. DOI · PMID 25363768
Whole-exome sequencing study (simplex families) · more than 2,500 simplex families

Related individual studies in the knowledge base (PubMed): 36450307 · 37031194

Vaccines do not cause autism – what the evidence shows

Large population and cohort studies covering several million children combined, as well as meta-analyses, find no association between vaccines – in particular the MMR vaccine (measles, mumps, rubella) – and autism. The same applies to the previously discussed preservative thimerosal and to the total number of vaccine antigens. The scientific consensus is unambiguous. The original paper by Wakefield (1998), which sparked the hypothesis, was formally retracted for serious methodological and ethical shortcomings.

Key findings

MMR, Denmark I: in a cohort of 537,303 children, vaccinated children showed no increased autism risk (relative risk 0.92; 95% CI 0.68-1.24) (Madsen 2002).
MMR, Denmark II: a cohort of 657,461 children confirmed this (hazard ratio 0.93; 95% CI 0.85-1.02) – even in higher-risk subgroups, such as siblings of autistic children, no increased risk (Hviid 2019).
Elevated baseline risk: even among 95,727 US children with older siblings – including siblings of autistic children – there was no association between MMR vaccination and autism (Jain 2015).
Meta-analysis: across roughly 1.26 million children (cohort studies), no association was found with vaccination (OR 0.99), MMR, thimerosal or mercury (Taylor 2014).
Antigen load/thimerosal: increasing exposure to antibody-stimulating antigens in the first two years of life was not associated with autism spectrum disorder (DeStefano 2013).
Cochrane review (138 studies, over 23 million participants): no evidence of an association between MMR and autism (rate ratio 0.93; 95% CI 0.85-1.01; moderate certainty of evidence) (Di Pietrantonj 2020).
Wakefield 1998: a case series of just 12 children with no control group; fully retracted by The Lancet in 2010 (listed in PubMed as a "Retracted Publication") – not an open controversy, but a debunked claim.

Context & limitations

The evidence comes mainly from very large observational studies (cohorts, case-control studies); randomized trials on the vaccination question would not be ethically justifiable. The strength of the evidence rests on very large samples and consistent replication across multiple countries and vaccine components. Autism has a strongly genetic basis and begins before or shortly after birth (see the topics on heritability and polygenic genetics); the timing overlap between the MMR vaccine (around 12-15 months) and the emergence of the first visible signs of autism explains how the misunderstanding of a causal link arose.

Studies & sources

Madsen KM, Hviid A, Vestergaard M, et al. (2002). A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 347(19):1477-82. DOI · PMID 12421889
Population-based cohort study (Denmark) · 537,303 children
Hviid A, Hansen JV, Frisch M, Melbye M. (2019). Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Ann Intern Med 170(8):513-520. DOI · PMID 30831578
Nationwide cohort study (Denmark) · 657,461 children
Jain A, Marshall J, Buikema A, et al. (2015). Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA 313(15):1534-40. DOI · PMID 25898051
Retrospective cohort study (USA) · 95,727 children with older siblings
Taylor LE, Swerdfeger AL, Eslick GD. (2014). Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine 32(29):3623-9. DOI · PMID 24814559
Meta-analysis (cohort and case-control studies) · 5 cohorts (1,256,407 children) + 5 case-control studies
DeStefano F, Price CS, Weintraub ES. (2013). Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism. J Pediatr 163(2):561-7. DOI · PMID 23545349
Case-control study (USA) · 256 children with ASD, 752 controls
Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. (2020). Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev 4(4):CD004407. DOI · PMID 32309885
Cochrane review / meta-analysis · 138 studies, over 23 million participants
Wakefield AJ, Murch SH, Anthony A, et al. (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351(9103):637-41. [RETRACTED 2010] DOI · PMID 9500320
Case series (12 children) – RETRACTED 2010 · 12 children

Screening vs. diagnosis in autism assessment

Screening and diagnostic assessment serve different purposes in identifying autism: screening tools such as the M-CHAT-R/F or the Social Communication Questionnaire (SCQ) identify, out of a broad group, children with an elevated likelihood, without themselves establishing a diagnosis; the actual assessment is carried out with diagnostic instruments such as ADOS-2 and ADI-R as part of a comprehensive, multidisciplinary evaluation. Professional bodies weigh the benefit of universal screening differently: the AAP recommends standardized screening at 18 and 24 months, whereas the US Preventive Services Task Force (USPSTF) considers the evidence for universal screening of asymptomatic children with no parental concerns to be insufficient. A positive screening result indicates an elevated risk – not a confirmed diagnosis; that remains reserved for an individual diagnostic assessment.

Key findings

Screening is not diagnosis: with the two-stage M-CHAT-R/F, children with a positive result had a 47.5% (95% CI 0.41-0.54) probability of an autism diagnosis and a 94.6% probability of some developmental delay – a positive screen therefore indicates elevated risk, not a diagnosis (Robins 2014).
Two-stage M-CHAT-R/F screening in early detection reduced the age at diagnosis by about 2 years compared with the national median (Robins 2014).
The Social Communication Questionnaire (SCQ, 40 questions; formerly the "Autism Screening Questionnaire") distinguished pervasive developmental conditions well from other diagnoses across all intelligence levels, with a cut-off of 15 as the most effective threshold; individual variants within the spectrum were distinguished less well (Berument 1999).
The USPSTF concludes that the current evidence is insufficient to weigh the benefits and harms of universal screening in asymptomatic children aged 18-30 months with no concerns from parents or professionals (I statement) – this is explicitly not a recommendation against screening (Siu 2016).
The AAP recommends standardized autism screening at 18 and 24 months in addition to ongoing developmental surveillance, since autism is common (reported US prevalence 1 in 59 children, about 1.7%) and can already be recognizable from around 18 months (Hyman 2020).
In diagnostic assessment, the ADOS-2 performed better than the ADI-R in a meta-analysis of 22 studies (ADOS-2: sensitivity 0.89-0.92, specificity 0.81-0.85; ADI-R: sensitivity 0.75, specificity 0.82) (Lebersfeld 2021).
The accuracy of the ADI-R was higher in research samples (specificity 0.85) than in clinical care (0.72) – so published figures cannot simply be carried over to everyday clinical practice without scrutiny (Lebersfeld 2021).
Brief overview of the instruments (purpose and age range): M-CHAT-R/F = parent-report screening for toddlers aged 16-30 months; SCQ = screening questionnaire for children from age 4 (developmental age over 2 years); ADOS-2 = standardized, direct behavioral observation (diagnostic) from a developmental age of 12 months into adulthood (Toddler Module 12-30 months); ADI-R = structured parent interview (diagnostic) from a developmental age of 2 years. ADOS-2 and ADI-R combined are considered the diagnostic gold standard, but do not replace the overall clinical judgment (Robins 2014; Yu 2023).

Context & limitations

These findings rest on different study types, each with its own scope. The M-CHAT-R/F validation (Robins 2014) is a large prospective two-stage screening study in early detection (16,071 toddlers) and provides predictive-power figures, not statements about cause. The SCQ validation (Berument 1999) is based on a case-control design with 200 people; such samples can overestimate discriminative power under everyday conditions with a lower base rate. The USPSTF (Siu 2016) and the AAP (Hyman 2020) weigh the same body of evidence differently – the USPSTF's "insufficient evidence" reflects a lack of adequate studies, not a recommendation against screening. The meta-analysis on ADOS-2 and ADI-R (Lebersfeld 2021, 22 studies) shows that published accuracy figures from research settings cannot be transferred unquestioningly to routine care. All accuracy figures are group-level statistical measures, not individual probabilities. The interdisciplinary German national guideline is the S3 guideline "Autism Spectrum Disorders, Part 1: Diagnosis" (AWMF 028-018); however, its validity expired in 2021 and it is currently being revised (checked as of July 2026: no updated version has been published yet). None of these sources determines whether autism is present in an individual case – that remains reserved for a comprehensive, individual assessment.

Studies & sources

Robins DL, Casagrande K, Barton M, et al. (2014). Validation of the Modified Checklist for Autism in Toddlers, Revised With Follow-up (M-CHAT-R/F). Pediatrics 133(1):37-45. DOI · PMID 24366990
Validation study (prospective two-stage screening) · 16,071 toddlers
Berument SK, Rutter M, Lord C, Pickles A, Bailey A. (1999). Autism screening questionnaire: diagnostic validity. Br J Psychiatry 175:444-51. DOI · PMID 10789276
Instrument validation (case-control design) · 200 people (160 PDD, 40 non-PDD)
Siu AL; US Preventive Services Task Force (USPSTF). (2016). Screening for Autism Spectrum Disorder in Young Children: US Preventive Services Task Force Recommendation Statement. JAMA 315(7):691-6. DOI · PMID 26881372
Official recommendation (USPSTF; I statement) · Target group: children 18-30 months with no concerns/parental worries
Hyman SL, Levy SE, Myers SM; AAP Council on Children With Disabilities. (2020). Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. Pediatrics 145(1):. DOI · PMID 31843864
Guideline / clinical report (AAP) · Consensus/review document
Lebersfeld JB, Swanson MN, Clesi CD, O'Kelley SE. (2021). Systematic Review and Meta-Analysis of the Clinical Utility of the ADOS-2 and the ADI-R in Diagnosing Autism Spectrum Disorders in Children. J Autism Dev Disord 51(11):4101-4114. DOI · PMID 33475930
Systematic review and meta-analysis (HSROC) · 22 studies
Yu Y, Ozonoff S, Miller M. (2023). Assessment of Autism Spectrum Disorder. Assessment 31(1):24-41. DOI · PMID 37248660
Review (screening & diagnostic instruments) · narrative review
DGKJP, DGPPN et al. (lead authors) (2016). Autism spectrum disorders in children, adolescents and adults, Part 1: Diagnosis (S3 guideline). Registry no. 028-018; validity expired 04/04/2021, currently under revision. AWMF
S3 guideline (interdisciplinary, evidence- & consensus-based) · National guideline (Germany)

Related individual studies in the knowledge base (PubMed): 37692637 · 37782510 · 30238166 · 28787504 · 26088658